Market Insights
Chronic kidney disease, also known as chronic renal disease or chronic kidney failure, is characterized by a progressive loss of kidney function over a period of time. Factors such as the rising geriatric population, the increase in the prevalence of CKD, and favorable reimbursement policies in some countries are driving the market growth of CKD drugs worldwide.
The report titled “Chronic Kidney Disease (CKD) Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall Chronic Kidney Disease (CKD) Drugs market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug class (antihypertensive, antihyperlipidemic, anemia treatment drugs, swelling treatment drugs, and other medications) and different geographical regions.
In order to help strategic decision-makers, the report also includes sections on the competitive profiling of the leading players in the global chronic kidney disease (CKD) drugs market, attractive investment propositions, and market positioning of key manufacturers. Other in-depth analysis provided in the report includes:
Geographically, the global chronic kidney disease (CKD) drugs market is studied for the following regional markets:
- North America
- Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global chronic kidney disease (CKD) drugs market.
Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global chronic kidney disease (CKD) drugs market.
This report concludes with a company profiles section that highlights major information about the key players engaged in the global chronic kidney disease (CKD) drugs market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global chronic kidney disease (CKD) drugs market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.
Based on drug class, the global chronic kidney disease (CKD) drugs market is segmented as follows:
Antihypertensive
- ACE Inhibitors
- Angiotensin-II Receptor Blockers
- Beta Blockers
- Calcium channel blockers
- Diuretics
- anemia treatment drugs
- Antihyperlipidemic Drugs
- Swelling treatment drugs
- Other
Chronic kidney disease, also known as chronic renal disease, is characterized by a gradual loss of kidney function over time. Factors such as the higher prevalence of CKD worldwide, the increasing incidence of diabetes and cardiovascular disease, and the rising geriatric population are driving the market growth of CKD drugs worldwide.
According to the Centers for Disease Control and Prevention (CDC), more than 10% of adults in the United States are affected by CKD, and patients with diabetes and hypertension are at higher risk of developing CKD. Approximately 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure have CKD.
It is observed that, in the base year 2016, antihypertensive medications held the largest market share because patients with CKD generally experience high blood pressure. There are different classes of medications used to treat high blood pressure in CKD, but it is estimated that ACE inhibitors and diuretics are the most widely used in the market as these are recommended as a first-line treatments. Erythropoietin-stimulating agents are extensively used in the market as anemia is a common complication associated with CKD.
For the purpose of this study, the global chronic kidney disease (CKD) drugs market is categorized into three segments:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
In the base year 2016, North America dominated the chronic kidney disease (CKD) drugs market, and the United States is a major revenue contributor because of factors such as the increase in the number of obese and diabetic patients, the higher cost of medication, promising pipeline molecules such as ABT-614 (Abbott Laboratories) and EOS-789 (Chugai Pharmaceutical), and an upsurge in funding by government agencies and private organizations in the healthcare system are driving the market growth of CKD medication in North America.
According to the Centers for Disease Control and Prevention, CKD affects more than 20 million people in the United States. Federal and state governmental agencies and various national organizations have developed thorough plans to handle CKD in the United States, which would further drive the market’s growth in North America. Europe is the second-largest revenue-generating regional market for CKD drugs due to the higher number of affected patients and higher cost of treatment.
It is anticipated that Asia Pacific will show the fastest growth during the forecast period due to the rising incidence of cardiovascular disorders and diabetes, continuous economic development, an increase in healthcare spending, populous countries, and improvements in healthcare infrastructure that will contribute to market growth in Asia Pacific during the forecast period of 2017–2025.
